Text size A A

News

Date Title and Summary Additional Formats
Toggle Summary AGTC to Participate in Cantor Fitzgerald Virtual Panel: Key Considerations for Gene Therapy Manufacturing and Platforms
GAINESVILLE, Fla. , and CAMBRIDGE, Mass. , Oct. 21, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company focused on developing adeno-associated virus (AAV) based gene therapies for the treatment of rare inherited diseases, today announced that
View HTML
Toggle Summary AGTC to Present at Upcoming Virtual Conferences
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Oct. 08, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company focused on developing adeno-associated virus (AAV) based gene therapies for the treatment of rare inherited diseases, today announced that
View HTML
Toggle Summary AGTC Joins the My Retina Tracker® Program as a New Scientific Collaborator
GAINESVILLE, Fla. , and CAMBRIDGE, Mass. , Oct. 07, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (AGTC), Blueprint Genetics, and Foundation Fighting Blindness , announce today that AGTC, a biotechnology company conducting human clinical trials of adeno-associated virus
View HTML
Toggle Summary AGTC Provides Trial Design Update for its Phase 2/3 XLRP Clinical Trial, New Data on XLRP Higher Dose Group and Financial Results for the Fourth Quarter and Year Ended June 30, 2020
- Planned Phase 2/3 trial expected to include approximately 60 patients and a responder analysis based on at least 7 decibel improvement in visual sensitivity in at least 5 loci across two active dose groups and one control group - - Data from Group 5 supports use of higher dose level in Phase 2/3
View HTML
Toggle Summary AGTC to Participate at Upcoming Virtual Investor Conferences
GAINESVILLE, Fla. , and CAMBRIDGE, Mass. , Sept. 03, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company focused on developing adeno-associated virus (AAV) based gene therapies for the treatment of rare inherited diseases, today announced that
View HTML
Toggle Summary AGTC to Host Management Update on September 9 at 8:00 am ET to Discuss Planned Phase 2/3 XLRP Trial, Share Additional XLRP Data and Report Fourth Quarter and Fiscal Year End 2020 Financial Results
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Sept. 02, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
View HTML
Toggle Summary AGTC Announces Publication of Preclinical Data that Support the Ongoing Clinical Development of Its XLRP Gene Therapy Program
Preclinical studies validate the transgene and dosing used in the ongoing Phase 1/2 clinical trial in patients with XLRP due to mutations in the RPGR gene GAINESVILLE, Fla. , and CAMBRIDGE, Mass. , Aug. 25, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a
View HTML
Toggle Summary AGTC Formalizes Patient Advisory Council to Provide Insights and Guidance on Patient Perspectives for Pipeline Therapies
Patient Advisory Council to include advocates from the inherited retinal diseases global community  New Patient Advisory Council to focus initially on Company ’ s clinical stage programs for X-linked retinitis pigmentosa (XLRP) GAINESVILLE, Fla. , and CAMBRIDGE, Mass. , Aug.
View HTML
Toggle Summary AGTC to Present at the Wedbush PacGrow Virtual Healthcare Conference on August 11, 2020
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Aug. 04, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
View HTML
Toggle Summary AGTC Announces Updated Development Plan for its X-Linked Retinitis Pigmentosa Clinical Program, Including Q1 2021 Start of Planned Phase 2/3 Trial
FDA feedback allows for forward program development Company reiterates that its favorable safety profile and its advanced manufacturing and analytics capabilities enable rapid clinical development GAINESVILLE, Fla. and CAMBRIDGE, Mass. , July 22, 2020 (GLOBE NEWSWIRE) -- Applied Genetic
View HTML
Visionary science for life changing cures.